[Anti-thrombotic therapy of acute coronary syndromes without ST elevation]
Gilles Montalescot1, Laurent Payot, Jean-Philippe Collet
1Institut de Cardiologie, Groupe Hospitalier Pitié-Salpétrière, AP-HP, 47, boulevard de l'Hôpital, 75013 Paris. gilles.montalescot@psl.ap-hop-paris.fr
Insights
Unstable angina, a common acute coronary syndrome, benefits from risk stratification. Aggressive combined antithrombotic therapy significantly reduces major coronary events and enhances early invasive strategies.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Context:
- Unstable angina represents the most frequent acute coronary syndrome.
- Effective risk stratification is crucial for predicting patient outcomes, including coronary morbidity, mortality, and hemorrhage risk.
Purpose:
- To highlight the efficacy of combined antithrombotic therapy in managing unstable angina.
- To underscore the role of risk stratification in guiding treatment decisions.
Summary:
- Combined antithrombotic therapy, incorporating aspirin, clopidogrel, low-molecular-weight heparin, and potentially glycoprotein IIb/IIIa receptor antagonists, has demonstrated significant reductions in major coronary events.
- This aggressive yet brief treatment regimen is well-tolerated and improves outcomes.
- The therapy synergizes with early invasive strategies, such as coronary angiography and stent-based percutaneous coronary angioplasty.
Impact:
- Substantial reduction in major coronary events associated with unstable angina.
- Improved tolerance and effectiveness of antithrombotic treatments.
- Enhanced success rates for early invasive cardiac procedures.
Abstract:
Unstable angina is the most frequent acute coronary syndrome. Risk stratification to predict coronary morbidity and mortality and the risk of major hemorrhage is the key element of the medical approach. Combined antithrombotic therapy (including aspirin, clopidogrel, low-molecular-weight heparin and, possibly, glycoprotein IIb/IIIa receptor antagonists) has led to a substantial reduction in major coronary events; tolerance is good because the treatment is brief and aggressive. Combined antithrombotic therapy also increases the benefit of early invasive strategies including coronary angiogram with stent-based percutaneous coronary angioplasty.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care